Skip to content
Biodatica
Start free

Angiodynamics, Inc.

Orange, California

Oncologyliquid biopsyPhase IIListed · ANGO

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

NIH R01 · $0.7M · Urothelial Resurfacing with Irreversible Electroporation for Adjuvant Therapy of Bladder Cancer

5w agoNew grantJun 10, 2026Source filing (opens the source filing in a new tab)

Momentum

77no change

Momentum 77 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $706k · non-dilutive

    Jun 11, 2026

    UNIVERSITY OF MASSACHUSETTS AMHERST · PI SRIMATHVEERAVALLI, GOVINDARAJAN · NCI · award ends May 31, 2031 · Urothelial Resurfacing with Irreversible Electroporation for Adjuvant Therapy of Bladder Cancer

    NIH RePORTER · NIH RePORTER 11225861 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Mar 29, 2022

    Prostate Cancer · COMPLETED · sponsor: Angiodynamics, Inc. · Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

    ClinicalTrials.gov · NCT04972097 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Dec 14, 2010

    Urothelial Carcinoma · COMPLETED · sponsor: Memorial Sloan Kettering Cancer Center · Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

    ClinicalTrials.gov · NCT01261728 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources